ORPHA:454836
Avian influenza
Publications
40,119
Trials
38
Interventional, condition-specific
Researchers
1,609
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare, infectious disease characterized by variable severity and outcome, ranging from mild upper respiratory tract infection with fever and cough, to influenza-like illness with rapid progression to severe pneumonia, sepsis with shock, acute respiratory distress syndrome and even death. Additional manifestations may include conjunctivitis, nausea, abdominal pain, diarrhea, vomiting, multiple organ dysfunction, and .
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018695
- MeSH:D005585
- UMLS:C0016627
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
40,119 matched papers (22,291 in last 10 years) Source
- Phenotype characterisedPresent
41 HPO annotations (e.g. Myalgia; Fatigue; Productive cough) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPartial
1 EMA designation (none yet with FDA orphan-indication approval) — e.g. anti-H5N1 equine immunoglobulin F(ab')2 fragments Source
- Interventional trialPresent
38 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
41
Associated phenotypes · MONDO:0018695
- Myalgia
- Fatigue
- Productive cough
- Meningitis
- Acute kidney injury
Showing 5 of 41 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- EMA anti-H5N1 equine immunoglobulin F(ab')2 fragmentsTreatment of avian influenza · 28/07/2015 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
2 associated chemicals · 8 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Active Hexose Correlated Compound · therapeutic
- Chloroquine · therapeutic
Pathways: Measles; Influenza A; ISG15 antiviral mechanism; Antiviral mechanism by IFN-stimulated genes; Cytokine Signaling in Immune system; Immune System; Interferon alpha/beta signaling; Interferon Signaling
Literature
Is anyone studying this?
40,119
40,119 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
40,119 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
22,291 in the last 10 years · low confidence
Phrase hits: 40,117 · MeSH hits: 109
Who's working on it?
1,609
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li J7 papers · 2026
Longhu Laboratory of Advanced Immunology, Zhengzhou, Henan, 450046, China; School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China; Henan Key Laboratory of Immunobiology, Zhengzhou, Henan, 450001, China.
Papers in Europe PMC - 02Wang X7 papers · 2026
Institute for Infectious Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.
Papers in Europe PMC - 03Günther A5 papers · 2026
Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.
Papers in Europe PMC - 04Li Y5 papers · 2026
Key Laboratory of Applied Biotechnology on Animal Science & Veterinary Medicine of Zhejiang Province, Zhejiang Engineering Research Center for Veterinary Diagnostics & Advanced Technology, Zhejiang International Science and Technology Cooperation Base for Veterinary Medicine and Health Management, Belt and Road International Joint Laboratory for One Health and Food Safety, China-Australia Joint Laboratory for Animal Health Big Data Analytics, College of Veterinary Medicine of Zhejiang A&F University, Hangzhou 311300, China.
Papers in Europe PMC - 05Li Z5 papers · 2026
Shandong Sinder Technology Co., Ltd., Zhucheng, 266100, China.
Papers in Europe PMC - 06Liu J5 papers · 2026
Department of Mathematics and Statistics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Papers in Europe PMC - 07Wang Y5 papers · 2026
College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, People's Republic of China.
Papers in Europe PMC - 08Wille M5 papers · 2026
WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Papers in Europe PMC - 09Yang J5 papers · 2026
Avian Influenza and Newcastle Disease Group, The Pirbright Institute, Woking, GU24 0NF, UK.
Papers in Europe PMC - 10Zhang J5 papers · 2026
College of Animal Science & Technology, Zhong kai University of Agriculture and Engineering, Guangzhou 510225, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
38
interventional trials for this specific condition
38 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 2,031 trials are registered for influenza, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
38 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.6th percentile).
low confidence · 96.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
38 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07240558·RECRUITING·Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
Not reviewed·Conditions: Influenza (Pandemic) · Avian Influenza · Vaccination·Matched via name phrase
- NCT06842173·RECRUITING·Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
Not reviewed·Conditions: Avian Influenza A Virus·Matched via name phrase
- NCT07678619·ENROLLING BY INVITATION·Smart Analysis and Decision-Making for Emerging Infectious Diseases
Not reviewed·Conditions: Emerging Infectious Diseases · COVID-19 · Influenza · Mpox (Monkeypox)·Matched via name phrase
Broader category: influenza
2,031
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07352462·NOT YET RECRUITING·Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath
Not reviewed·Conditions: Respiratory Infections · COVID-19 · Influenza Virus Infection · Legionella Pneumophila Infections·Matched via name phrase
- NCT04366115·NOT YET RECRUITING·Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Not reviewed·Conditions: ARDS · Covid19 · Influenza, Human·Matched via name phrase
- NCT07110532·RECRUITING·pH1N1 Blinded Challenge Study
Not reviewed·Conditions: Influenza·Matched via name phrase
- NCT06753474·RECRUITING·A/Texas Flu Challenge
Not reviewed·Conditions: Influenza·Matched via name phrase
- NCT07291635·RECRUITING·Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
Not reviewed·Conditions: Influenza·Matched via name phrase
- NCT07217639·NOT YET RECRUITING·Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
Not reviewed·Conditions: COVID -19 · Influenza A · Influenza B · Respiratory Synctial Virus·Matched via name phrase
- NCT06599658·RECRUITING·COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Not reviewed·Conditions: COVID 19 · Influenza · Rheumatoid Arthritis (RA) · Systemic Lupus Erthematosus·Matched via name phrase
- NCT07721649·NOT YET RECRUITING·Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
Not reviewed·Conditions: Acute Coronary Syndrome · Heart Failure · Influenza, Human · Cardiovascular Diseases·Matched via name phrase
- NCT07349017·NOT YET RECRUITING·A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)
Not reviewed·Conditions: Influenza·Matched via name phrase
- NCT07359287·RECRUITING·Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
Not reviewed·Conditions: Angina · Acute Bronchiolitis · Acute Bronchitis · COPD Exacerbation (AECOPD)·Matched via name phrase
- NCT07126652·NOT YET RECRUITING·Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial
Not reviewed·Conditions: Antibody Response·Matched via name phrase
- NCT05291676·RECRUITING·Systems Investigation of Vaccine Responses in Aging and Frailty
Not reviewed·Conditions: Influenza·Matched via name phrase
- NCT07169318·RECRUITING·First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
Not reviewed·Conditions: Influenza·Matched via name phrase
- NCT05108818·RECRUITING·Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
Not reviewed·Conditions: Influenza, Human·Matched via name phrase
- NCT07420985·RECRUITING·Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
Not reviewed·Conditions: Influenza · Acute Respiratory Viral Infection·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- ctis·2025-522116-16-00·Cancelled·Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.
skipped — LLM skipped (--skip-llm)
- ctis·2024-515436-76-00·Cancelled·The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.
skipped — LLM skipped (--skip-llm)
- ctis·2023-509178-44-00·Authorised, ongoing·Avian and seasonal influenza vaccine induced immune responses
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99840298·Recruiting·Understanding the immune response to West Nile and Usutu Viruses
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70837239·No longer recruiting·Evaluation of heterosubtypic immune responses in older people
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN43083885·No longer recruiting·High dose versus standard dose oseltamivir for the treatment of severe influenza and avian influenza
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53344556·No longer recruiting·Randomised, Double-blinded, Placebo-controlled Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN07092892·No longer recruiting·A double blind study of dexamethasone for the treatment of H5N1 Avian Influenza
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Avian influenza — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Avian influenza"
MeSH descriptor terms unioned into the query: Influenza in Birds
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Avian influenza" OR "Influenza in Birds"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 38 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"influenza"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (40119) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T16:44:20.638Z
